What happened to larazotide clinical trials?

Larazotide showed promise in Phase 2b trials where the 0.5 mg dose significantly reduced celiac symptoms compared to placebo in 342 patients. However, the Phase 3 CeDLara trial was discontinued in 2022 after an interim analysis showed the study would need a prohibitively large sample size to reach statistical significance. Community interest persists because the mechanism (zonulin antagonism) remains scientifically valid.

Is larazotide effective for non-celiac leaky gut?

Community members report using larazotide for general intestinal permeability concerns beyond celiac disease. While the zonulin pathway is involved in various conditions affecting gut permeability, clinical evidence only exists for celiac disease. Anecdotal reports suggest some users experience reduced GI symptoms, but controlled data outside celiac disease is lacking.

Larazotide: Community Protocols & Reports

Q: Can larazotide be used as a gluten shield?

Some community members use larazotide before meals containing gluten as protection, but this was not how it was studied in clinical trials. All trial participants maintained a gluten-free diet. Larazotide may reduce but likely does not eliminate gluten-induced intestinal permeability changes. It should not be considered a substitute for a gluten-free diet in celiac disease.

Aggregated community experiences, protocols, and stacking patterns

Anecdotal ReportsBased on 25 community reports

Community-Sourced Information

The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.

For peer-reviewed dosing protocols, see the clinical dosing guide.

Browse community protocols for all 130 peptides →

✓Reviewed byEditorial Team

📅Updated February 16, 2026

Unverified

📌TL;DR

•3 community protocols documented
•Evidence level: Anecdotal Reports
•Based on 25 community reports
•2 stacking patterns reported

Clinical vs. Community Protocol Differences

How community-reported protocols differ from clinical research protocols.

Aspect	Clinical Approach	Community Approach	Significance
Indication Scope	Clinical trials exclusively studied larazotide in celiac disease patients on a gluten-free diet, measuring symptom improvement and intestinal permeability markers.	Community use extends to general leaky gut, non-celiac gluten sensitivity, autoimmune conditions, and as part of SIBO/dysbiosis protocols. Many users are not formally diagnosed with celiac disease.	high Larazotide's zonulin antagonist mechanism may have relevance beyond celiac disease, but clinical evidence only exists for celiac patients.
Dose Selection	Phase 2b trial tested 0.5, 1, and 2 mg three times daily. Only the 0.5 mg dose showed statistically significant symptom improvement vs placebo.	Community typically uses the 0.5 mg dose based on clinical data. Some users experiment with higher doses despite the Phase 2b finding that higher doses were not superior.	moderate The clinical finding that only 0.5 mg was effective is well-known in the community, making this one of the more evidence-aligned community protocols.
Treatment Context	All trial participants maintained a gluten-free diet during treatment. No gluten challenge was required. Larazotide was studied as adjunctive therapy.	Some community members use larazotide as protection when intentionally consuming gluten, treating it as a gluten shield rather than adjunctive therapy on a gluten-free diet.	high Using larazotide as a gluten shield was not studied in clinical trials. The peptide may reduce but not eliminate gluten-induced immune activation.

Compare these community approaches with published research findings.

Community Protocols

Standard Gut Permeability Protocol

Popular

Route: Oral
Dose: 0.5 mg
Frequency: Three times daily (before meals)
Duration: 8-12 weeks

Mirrors the Phase 2b clinical trial dose that showed statistical significance; taken 15 minutes before meals

Low-Dose Maintenance Protocol

Niche

Route: Oral
Dose: 0.25 mg
Frequency: Three times daily
Duration: Ongoing

Lower dose for ongoing gut permeability support; used by those with celiac disease on gluten-free diets

Leaky Gut Protocol

Common

Route: Oral
Dose: 0.5-1 mg
Frequency: Three times daily
Duration: 4-8 weeks

Used beyond celiac disease for general intestinal permeability concerns; community extension of clinical indications

Stacking Patterns

Gut Barrier Repair Stack

Common

Larazotide for tight junction regulation combined with BPC-157 for mucosal healing; comprehensive gut barrier restoration approach

larazotide bpc-157

Gut Inflammation + Permeability Stack

Niche

Larazotide for mechanical barrier function with KPV for NF-kB-mediated anti-inflammatory action in the intestinal mucosa

larazotide kpv

Check stack compatibility and review potential side effects before combining peptides.

Unlock community dosing protocols and stacking combos

See the exact doses, routes, and schedules 25+ self-experimenters report. Free with email.

150+ peptide profiles · 30+ comparisons · 18 research tools

Already subscribed?

Sources

Reddit r/Celiac|Larazotide and celiac disease management discussions(accessed 2026-02-16)
Celiac.com Forum|To those in the Larazotide Acetate trial, how is it going?(accessed 2026-02-16)
Beyond Celiac|Larazotide Acetate launches Phase 3 trial(accessed 2026-02-16)
Reddit r/Peptides|Larazotide for gut permeability and leaky gut discussions(accessed 2026-02-16)

Community Evidence Overview#

This page presents aggregated community protocols and anecdotal reports for Larazotide (AT-1001). The information below is gathered from celiac disease forums, peptide communities, and patient experience reports. This is not clinical evidence and should not be used as medical guidance.

Larazotide occupies a unique position in the peptide community because it has substantial clinical trial data (Phase 2b with 342 patients) providing a relatively strong evidence base for community protocols. However, the discontinuation of the Phase 3 trial in 2022 means the peptide remains unapproved, and community access is limited.

Understanding Protocol Divergence#

Indication Expansion#

The most significant divergence is that community use extends well beyond the studied indication of celiac disease. Users apply larazotide to general leaky gut, non-celiac gluten sensitivity, autoimmune conditions, and gut dysbiosis. While the zonulin pathway has broad relevance to intestinal permeability, clinical evidence only supports use in celiac patients.

The Gluten Shield Concept#

Some community members use larazotide as pre-meal protection when consuming gluten, treating it as a pharmacological shield. This application was not studied in clinical trials, where all participants maintained a gluten-free diet. Larazotide may reduce but almost certainly does not eliminate gluten-induced immune activation.

Commonly Reported Outcomes#

Community members and clinical trial participants report the following:

Reduced GI symptoms: Decreased bloating, abdominal pain, and diarrhea in celiac patients
Improved gluten tolerance: Some community members report reduced symptoms after accidental or intentional gluten exposure
Onset timeline: Symptom improvements typically reported within 1-2 weeks of consistent use
Dose response: The 0.5 mg dose is most commonly reported as effective, consistent with Phase 2b findings

Important Caveats#

Phase 3 trial was discontinued, leaving efficacy questions unresolved
Community access to pharmaceutical-grade larazotide is extremely limited
Using larazotide as a gluten substitute was not clinically studied
Non-celiac applications lack any clinical evidence

Subscribe to see vendor options

Free access to verified vendor scores, pricing, and suppliers.